Shionogi is committed to applying our patient-first approach in everything we do to develop innovative medicines. Our research-led culture is defined by a distinct openness and close partnership approach to discovering and developing medicines addressing serious unmet medical needs. Our development approach goes hand-in-hand with the collaborative drug discovery process that lies at the heart of Shionogi.

Shionogi has remained committed to the development of anti-infectives, recognising antimicrobial resistance (AMR) as a crucial public health challenge and an area of unmet need. We are proud of our ongoing commitment to the research and development of antimicrobial therapies and are working hard to ensure that individual patients and society as a whole continue to benefit from effective drugs to combat AMR.